The molecular landscape of premenopausal breast cancer

Serena Liao, Ryan J. Hartmaier, Kandace P. McGuire, Shannon L. Puhalla, Soumya Luthra, Uma R. Chandran, Tianzhou Ma, Rohit Bhargava, Francesmary Modugno, Nancy E. Davidson, Steve Benz, Adrian V. Lee, George C. Tseng, Steffi Oesterreich

Research output: Contribution to journalArticle

Abstract

Introduction: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. Methods: Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. Results: PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. Conclusion: Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.

Original languageEnglish (US)
Article number104
JournalBreast Cancer Research
Volume17
Issue number1
DOIs
StatePublished - Aug 7 2015
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Laminin
Gene Expression
Integrins
Protein Array Analysis
Mutation
Gene Dosage
DNA Methylation
Multigene Family
Group Psychotherapy
Estrogen Receptors
Methylation
Databases
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liao, S., Hartmaier, R. J., McGuire, K. P., Puhalla, S. L., Luthra, S., Chandran, U. R., ... Oesterreich, S. (2015). The molecular landscape of premenopausal breast cancer. Breast Cancer Research, 17(1), [104]. https://doi.org/10.1186/s13058-015-0618-8

The molecular landscape of premenopausal breast cancer. / Liao, Serena; Hartmaier, Ryan J.; McGuire, Kandace P.; Puhalla, Shannon L.; Luthra, Soumya; Chandran, Uma R.; Ma, Tianzhou; Bhargava, Rohit; Modugno, Francesmary; Davidson, Nancy E.; Benz, Steve; Lee, Adrian V.; Tseng, George C.; Oesterreich, Steffi.

In: Breast Cancer Research, Vol. 17, No. 1, 104, 07.08.2015.

Research output: Contribution to journalArticle

Liao, S, Hartmaier, RJ, McGuire, KP, Puhalla, SL, Luthra, S, Chandran, UR, Ma, T, Bhargava, R, Modugno, F, Davidson, NE, Benz, S, Lee, AV, Tseng, GC & Oesterreich, S 2015, 'The molecular landscape of premenopausal breast cancer', Breast Cancer Research, vol. 17, no. 1, 104. https://doi.org/10.1186/s13058-015-0618-8
Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR et al. The molecular landscape of premenopausal breast cancer. Breast Cancer Research. 2015 Aug 7;17(1). 104. https://doi.org/10.1186/s13058-015-0618-8
Liao, Serena ; Hartmaier, Ryan J. ; McGuire, Kandace P. ; Puhalla, Shannon L. ; Luthra, Soumya ; Chandran, Uma R. ; Ma, Tianzhou ; Bhargava, Rohit ; Modugno, Francesmary ; Davidson, Nancy E. ; Benz, Steve ; Lee, Adrian V. ; Tseng, George C. ; Oesterreich, Steffi. / The molecular landscape of premenopausal breast cancer. In: Breast Cancer Research. 2015 ; Vol. 17, No. 1.
@article{d82ebaf1165a4905bcfbebe082786b6b,
title = "The molecular landscape of premenopausal breast cancer",
abstract = "Introduction: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. Methods: Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. Results: PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. Conclusion: Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.",
author = "Serena Liao and Hartmaier, {Ryan J.} and McGuire, {Kandace P.} and Puhalla, {Shannon L.} and Soumya Luthra and Chandran, {Uma R.} and Tianzhou Ma and Rohit Bhargava and Francesmary Modugno and Davidson, {Nancy E.} and Steve Benz and Lee, {Adrian V.} and Tseng, {George C.} and Steffi Oesterreich",
year = "2015",
month = "8",
day = "7",
doi = "10.1186/s13058-015-0618-8",
language = "English (US)",
volume = "17",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The molecular landscape of premenopausal breast cancer

AU - Liao, Serena

AU - Hartmaier, Ryan J.

AU - McGuire, Kandace P.

AU - Puhalla, Shannon L.

AU - Luthra, Soumya

AU - Chandran, Uma R.

AU - Ma, Tianzhou

AU - Bhargava, Rohit

AU - Modugno, Francesmary

AU - Davidson, Nancy E.

AU - Benz, Steve

AU - Lee, Adrian V.

AU - Tseng, George C.

AU - Oesterreich, Steffi

PY - 2015/8/7

Y1 - 2015/8/7

N2 - Introduction: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. Methods: Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. Results: PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. Conclusion: Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.

AB - Introduction: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. Methods: Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. Results: PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. Conclusion: Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=84938591277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938591277&partnerID=8YFLogxK

U2 - 10.1186/s13058-015-0618-8

DO - 10.1186/s13058-015-0618-8

M3 - Article

VL - 17

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 104

ER -